Gyre Therapeutics Inc
GYRE
Get informed when a big investor buys or sells
+ FollowMarket Cap$784.88M
Close$
$-1.71
128.1% downside
Current Fair Value
128.1% downsideOvervalued by 128.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $784.88 Million |
|---|---|
| Enterprise Value | $747.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.06 |
| Beta | 4.74 |
| Outstanding Shares | 100,637,599 |
Return
| Return on Equity | -11.75% |
|---|---|
| Return on Assets | -6.36% |
| Return on Invested Capital | 6.57% |
Valuation & Multiples
| P/E Ratio | -35.39 |
|---|---|
| PEG | 1.29 |
| Price to Sales | 6.08 |
| Price to Book Ratio | 6.08 |
| Enterprise Value to Revenue | 6.26 |
| Enterprise Value to EBIT | 66.71 |
| Enterprise Value to Net Income | -59 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$32.96 M
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$28.40 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 9.69% |
|---|---|
| Total Invested | $3,013▼ 99.99% |
| Investors Holding | 2▼ 60.00% |
ESG Score
No data
About Gyre Therapeutics Inc
35 employees
CEO: Nassim Usman catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clin...